CD28 and neoplasm: In addition, in patients with B-cell acute lymphoblastic leukemia (B-ALL) with a high rate of tumor load, CD28-based CAR-T induced a higher incidence of CRS and neurotoxicity, shorter long-term survival, and ineffective resistance to disease recurrence (NCT01044069) (37).